ZBIO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zenas BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.00 |
| 52 Week High | US$26.25 |
| 52 Week Low | US$9.45 |
| Beta | 0 |
| 11 Month Change | -41.18% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.5% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how ZBIO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ZBIO performed against the US Market.
Price Volatility
| ZBIO volatility | |
|---|---|
| ZBIO Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ZBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 115 | Lonnie Moulder | zenasbio.com |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. Fundamentals Summary
| ZBIO fundamental statistics | |
|---|---|
| Market cap | US$501.49m |
| Earnings (TTM) | -US$128.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs ZBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$110.40m |
| Gross Profit | -US$110.40m |
| Other Expenses | US$18.57m |
| Earnings | -US$128.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZBIO perform over the long term?
See historical performance and comparison